 MUMBAI, India, March 23, 2021 PRNewswire -- Cipla Therapeutics, an affiliate of Cipla Limited BSE: 500087 NSE: CIPLA EQ herein referred to as Cipla and SIGA Technologies, Inc. SIGA NASDAQ: SIGA, a commercial-stage pharmaceutical company focused on the health security market announced entering into a strategic partnership to deliver sustained innovation and access to novel antibacterial drugs, particularly against biothreats. The World Health Organization has declared that anti-microbial resistance AMR is one of the top 10 global public health threats facing humanity2 which puts at risk the effective prevention and treatment of a wide range of infections. 